Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer study aims to see how well osimertinib works in everyday practice

NCT ID NCT07028489

Knowledge-focused Sponsor: N-Power Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study is collecting information from 130 people with advanced EGFR-mutant non-small cell lung cancer who are starting treatment with osimertinib. Researchers want to see how long the drug controls the cancer in real-world settings, outside of strict clinical trial conditions. Participants will have their health data recorded at regular visits, and some will have scheduled imaging scans. The goal is to better understand how well osimertinib works in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
osimertinib
What this could lead to
If successful, this study could provide better real-world evidence on how well osimertinib works for EGFR-mutant lung cancer, helping doctors make more informed treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. It does not test a new drug or intervention, so it cannot directly lead to a cure or new therapy. Results may also be limited by the specific patient group and data collection methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients diagnosed with EGFR mutant locally advanced or metastatic NSCLC diagnosed from Jan 1st 2024 until the enrollment period ends.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA * Be ≥18 years of age at the time of informed consent * Evidence of a confirmed diagnosis of EGFR mutant (EGFR exon 19del or EGFR exon 21 L858R) locally advanced or metastatic NSCLC diagnosed on Jan 1st 2024 or later. EXCLUSION CRITERIA * ECOG≥2 at diagnosis of advanced or metastatic NSCLC * Evidence of prior treatment with osimertinib, amivantamab or lazertinib. For the planned selection and analysis of external controls, further eligibility criteria will be applied according to the COPERNICUS SAP.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    9 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bayhealth Cancer Center- Kent

    RECRUITING

    Dover, Delaware, 19901, United States

    Contact Email: •••••@•••••

  • Bayhealth Cancer Center- Sussex

    RECRUITING

    Milford, Delaware, 19963, United States

    Contact Email: •••••@•••••

  • John Muir Health

    RECRUITING

    Walnut Creek, California, 94598, United States

  • Kootenai Clinic Cancer Services Coeur d'Alene

    RECRUITING

    Coeur d'Alene, Idaho, 83814, United States

  • Lankenau Medical Center

    NOT_YET_RECRUITING

    Paoli, Pennsylvania, 19301, United States

  • Northwest Oncology & Hematology

    RECRUITING

    Elk Grove Village, Illinois, 60007, United States

  • Oncology Consultants, P.A.

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Pacific Cancer Care

    RECRUITING

    Monterey, California, 93940, United States

  • Torrance Memorial Physician Network-Cancer Care

    RECRUITING

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.